Innate Pharma SA
OTC:IPHYF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Innate Pharma SA
OTC:IPHYF
|
FR |
|
S
|
SEB SA
XMUN:GRB
|
FR |
|
EQT AB
STO:EQT
|
SE |
|
B
|
Bangkok Union Insurance PCL
SET:BUI
|
TH |
|
E
|
Expion360 Inc
NASDAQ:XPON
|
US |
|
L
|
L'Air Liquide Societe Anonyme pour l'Etude et l'Exploitation des Procedes Georges Claude SA
XMUN:AIL
|
FR |
|
Lincoln Gold Mining Inc
XTSX:LMG
|
CA |
|
Strongpoint ASA
OSE:STRO
|
NO |
|
P
|
PayPal Holdings Inc
XETRA:2PP
|
US |
|
D
|
Datalogic SpA
MIL:DAL
|
IT |
|
Singapore Telecommunications Ltd
SGX:Z74
|
SG |
|
IMCD NV
OTC:IMCDY
|
NL |
Wall St Price Targets
IPHYF Price Targets Summary
Innate Pharma SA
According to Wall Street analysts, the average 1-year price target for IPHYF is 4.8 USD with a low forecast of 4 USD and a high forecast of 5.73 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is IPHYF's stock price target?
Price Target
4.8
USD
According to Wall Street analysts, the average 1-year price target for IPHYF is 4.8 USD with a low forecast of 4 USD and a high forecast of 5.73 USD.
What is the Revenue forecast for Innate Pharma SA?
Projected CAGR
92%
Over the last 14 years, the compound annual growth rate for Revenue has been -7%. The projected CAGR for the next 7 years is 92%.
What is the Gross Profit forecast for Innate Pharma SA?
Projected CAGR
1 086%
The compound annual growth rate for Gross Profit over the next 3 years is 1 086%.
